Calendar

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Avadel Pharmaceuticals.

You won't want to miss this opportunity to learn more about narcolepsy, a rare, chronic and debilitating neurological condition, current unmet needs and an investigational, innovative treatment option. 

During this webinar, we will review:
Narcolepsy; burden of disease.
Overview of available treatments & unmet needs.
Efficacy and safety of LUMRYZ, an investigational extended-release sodium oxybate, designed to be taken once-at-bedtime.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Sanofi.

Respiratory Syncytial Virus (RSV) is associated with significant disease burden, especially in the infant population.  Nirsevimab is a candidate monoclonal Antibody (mAb) to prevent medically attended (MA) lower respiratory tract infection (LRTI) associated with RSV. During this presentation, the following will be discussed:
a. RSV Burden of Disease in All Infants
b. Need for All Infant Protection
c. Introduction to Nirsevimab, a candidate mAb to prevent MA LRTI due to RSV 
d. Clinical Development Program

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by UCB, Inc.

Generalized mysathenia gravis (gMG) is a rare, chronic, autoimmune neuromuscular disease in which the treatment landscape is rapidly evolving. This webinar will discuss:

• Overview of disease state and current treatment landscape.
•  Zilucoplan product profile and data from clinical trials.

This is a pre-approval information exchange (PIE) webinar for the purpose of coverage or reimbursement education.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Ascendis Pharma, Inc.

A presentation providing an update on Hypoparathyroidism and clinical data investigating its treatment with TransCon PTH (palopegteriparatide).

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Sage Therapeutics and Biogen.

There is an unmet need faced by the diverse population struggling with major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational product for the treatment of MDD and PPD.

The following will be discussed during the presentation:

• Burden of MDD and PPD
• Zuranolone product profile and clinical program

Zuranolone is an investigational compound that has not been FDA-approved for use; therefore, its safety and efficacy have not been established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA.